2025-05-19 HC Andersen – Julie Waras Brogren Julie Waras Brogren, Deputy CEO presents first quarter 2025 highlights at HC Anderse
2025-04-03 Interview with Andreas Norlin, CSO Andreas Norlin, Chief Scientific Officer at Ascelia Pharma shares insights into the company’s latest developments and our plan for the NDA submission
2025-02-07 HC Andersen – Full year and Q4 2024 report with Julie Waras Brogren HC Andersen - Q3 2024 report with Julie Waras Brogren
2025-01-29 Redeye Fight Cancer Event – January 22nd, 2025 Magnus Corfitzen, CEO at Ascelia Pharma AB presented at Redeye Fight Cancer Event
2024-11-13 HC Andersen – Q3 2024 report with Julie Waras Brogren HC Andersen - Q3 2024 report with Julie Waras Brogren
2024-09-10 HC Andersen – Q&A with Magnus Corfitzen Magnus Corfitzen, CEO presents at HC Andersen - Final outcome of Rights issue
2024-08-22 Carnegie – Interview CEO Magnus Corfitzen presents at Carnegie sharing insights on strong phase 3 results, rationale for the Rights issue 2024 and key milestones ahead
2024-08-22 Interview with Redeye Magnus Corfitzen, CEO at Ascelia Pharma AB shared his insights on the timeline for the NDA submission of Orviglance and the ongoing Rights Issue.
2024-08-22 HC Andersen – Update on Q2 2024 and Rights issue Julie Waras Brogren, Deputy CEO presents at HC Andersen
2024-08-13 HC Andersen Podcast – Business update Magnus Corfitzen, CEOpresent at the HC Andersen Podcast
2024-06-17 Ascelia Pharma – Commercial and partnership strategy Julie Waras Brogren, Deputy CEO presents at HC Andersen
2024-06-12 Interview with Redeye: commercial update and progress after successful Sparkle results Deputy CEO Julie Waras Brogren presents at Redeye
2024-06-04 HC Andersen – Life Science Seminar Magnus Corfitzen, CEO presents at the Life Science Seminar